Scientific Resources

hero-background-image
RoukenBio - IndEx-2 Deciphering the impact of antigen density on tumour targeting therapeutics.png

https://website-content.rouken.bio/whitepaper_58d636e133.svgWhitepapers

|

7 July 2023

|

5 min read

IndEx-2: Deciphering the impact of antigen density on tumour targeting therapeutics

Find out more about our new inducible cell line development model, IndEx-2, by reading through our latest whitepaper.

RoukenBio - A complete workflow for functional reversal of Treg mediated suppression.png

https://website-content.rouken.bio/whitepaper_58d636e133.svgWhitepapers

|

4 November 2022

|

7 min read

A complete workflow for functional reversal of Treg mediated suppression - Treg function, Treg suppression and your therapeutic candidate

Our Treg suppression assay formats are adaptable, using natural Tregs isolated from PBMCs, or induced Tregs expanded and differentiated from naïve CD4+ T cells.

RoukenBio - Best practices in cell line development - Utilising lentiviruses for cell line engineering.png

https://website-content.rouken.bio/whitepaper_58d636e133.svgWhitepapers

|

19 October 2022

|

6 min read

Best practices in cell line development - Utilising lentiviruses for cell line engineering

Target cells are a critical component of immune cell effector assays. Whether investigating TDCC or ADCC, we create engineered target cells uniquely suited for the evaluation of effector function and molecule specificity. But how do we achieve this and what are the principles we follow?

RoukenBio - Potency assay development considerations.png

https://website-content.rouken.bio/whitepaper_58d636e133.svgWhitepapers

|

18 October 2022

|

5 min read

Potency assay development considerations

Successful approval of biological medicinal products in the EU and US requires characterisation of the biological product’s properties to enable the setting of specifications that control the molecule’s critical quality attributes (CQA) for release into the clinic and onto the market. Release specifications ensure manufacturing lot-to-lot consistency, product stability, and ultimately, patient safety. So, what are the main development considerations? We delve into these to future-proof your potency assays.

Join our community of curious minds on LinkedIn

🗓️ Stay informed with our monthly scientific newsletter, published on LinkedIn on the last Wednesday of each month.

These editions bring you the latest in drug development breakthroughs, industry trends, and expert insights from the brilliant minds at RoukenBio.

Subscribe today on LinkedIn

Propel drug discovery breakthroughs with RoukenBio

Difficulty doesn’t deter us; it inspires us. Give us a problem, and we’ll find your solution. Our versatile specialists embrace every obstacle as an opportunity to showcase our innovative thinking and problem-solving prowess.

RoukenBio - Capabilities brochure.pngcta-image